Mainz Biomed has announced a strategic collaboration with Bioclinica to support the commercialisation of its ColoAlert test in Romania.
ColoAlert is a user-friendly at-home detection test for colorectal cancer (CRC).
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
By analysing tumour DNA, this non-invasive test provides better early detection of tumours compared to faecal occult blood tests.
The test, which is based on polymerase chain reaction technology, enables an earlier diagnosis and can identify more colorectal cancer cases than other stool tests.
ColoAlert is expected to benefit more than six million people aged between 50 and 74 years in Romania, a country with one of the highest CRC incidence rates in Europe.
Mainz Biomed chief commercial officer Darin Leigh said: “In executing our commercial strategy, we remain steadfast in aligning ourselves with laboratories that share our unwavering dedication to introducing cutting-edge diagnostic tests capable of making a profound impact on the treatment and prevention of critical diseases like CRC.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“Early detection is paramount in enhancing patient survival rates and our partnership with Bioclinica in Romania exemplifies our commitment to this cause.”
The company is already marketing ColoAlert in select European Union countries via direct sales, corporate health programmes and independent laboratories network.
It is also being assessed in the US Food and Drug Administration registration study, ReconAAsense, which will help secure marketing approval in the country.
Bioclinica offers modern diagnostics to people in Romania through its 15 associated laboratories and 146 collection points.
